SPH Biocad HK

SPH Biocad is a strategic joint venture established in 2019 between Shanghai Pharmaceuticals and the Russian biotechnology leader Biocad. Headquartered in Hong Kong with significant operations in Shanghai, the company is dedicated to the development, manufacturing, and commercialization of Biocad's portfolio of biosimilars and innovative biologics within the Greater China region. Its pipeline focuses on high-value monoclonal antibodies for oncology and autoimmune diseases, including biosimilars of bevacizumab and trastuzumab, as well as innovative therapies like netakimab and progolimab. By leveraging Biocad's advanced R&D and Shanghai Pharma's extensive clinical and distribution networks, SPH Biocad aims to enhance patient access to critical biologic treatments. The venture represents a major cross-border collaboration aimed at localizing high-tech biopharmaceutical production in China.